|Bid||6.10 x 1400|
|Ask||6.40 x 800|
|Day's Range||6.10 - 6.24|
|52 Week Range||4.20 - 13.70|
|Beta (3Y Monthly)||3.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its interaction with the FDA related to the chemistry, manufacturing and controls (CMC) package that will be needed to support Neutrolin’s new drug application (NDA). The FDA was supportive of Neutrolin’s proposed manufacturing program, including the active pharmaceutical ingredients (API), the container closure and testing, and indicated that it will conduct a thorough review of all of the CMC information as well as assess the commercial readiness of the various manufacturing facilities at the time of NDA filing. No further CMC meetings with FDA are planned prior to NDA submission.
BERKELEY HEIGHTS, N.J., Sept. 26, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for.
The combination of this transaction, the completion of the Exchange Agreement with funds managed by Elliott Management Corporation earlier this month, and exercises and expirations since June 30, 2019 of warrants held by other investors has resulted in the Company receiving gross proceeds of approximately $10 million and reducing its warrant overhang by approximately 2.9 million shares.
BERKELEY HEIGHTS, N.J., Sept. 03, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for.
In connection with the Exchange Agreement, Elliott has agreed to make a cash payment of $2 million and to exchange all of its outstanding warrants, 10% Senior Secured Convertible Notes (the principal and accrued interest of which would have amounted to a repayment obligation of approximately $10.1 million or been convertible into approximately 1.35 million shares if held to maturity), and Series C-2, Series D and Series F Convertible Preferred Stock for new Series G Convertible Preferred Stock. The new Series G Convertible Preferred Stock is convertible into an aggregate of 5,560,138 shares of Common Stock, subject to a claw back of up to 139,769 shares of Common Stock, depending upon the occurrence of certain stock price-related conditions. Elliott is retaining the shares of Common Stock and Series E Preferred Stock that it currently holds. With the completion of this exchange, the Company will have raised additional capital, will be debt-free and will have substantially reduced the amount of outstanding warrants as well as its classes of outstanding preferred stock. A Special Committee of the Board of the Company, consisting of independent directors with no relationship to Elliott, after consulting with independent financial advisors, determined that the Exchange Agreement was in the best interests of the Company and recommended it to the Board for approval.
CorMedix (CRMD) delivered earnings and revenue surprises of -9.09% and -73.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
BERKELEY HEIGHTS, N.J., Aug. 13, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BERKELEY HEIGHTS, N.J., Aug. 01, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
It's always hard to describe stocks that are trading under $10. Are they cheap stocks? Are they penny stocks? Are small-cap stocks bargains?Source: Shutterstock The fact is, a low-priced stock doesn't necessarily mean anything other than that it's low-priced. There's no reason to take a flyer on a low-priced stock just because it's low priced when a higher-priced stock (and few less shares) may get you a better stock.I do the same amount of leg work on every stock, regardless of its price. Then, once they've been through my Portfolio Grader system, I can parse that list by industry, momentum, fundamentals or in this case, price.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe seven A-rated stocks under $10 featured here have everything going for them, just like their higher-priced brethren. They just cost you a little less to get into. Or, you can take a bigger stake than you could in say a $30 stock. * The 10 Best Stocks to Invest in for August What's more, small-cap stocks (usually one and the same as low-priced stocks) are doing well now -- the Russell 2000 Index is the best indicator of the small caps, and it's up more than 14% year-to-date. And since they have been in the shadows while the big names get the glory, they're usually better values here as well. Orion Energy Systems (OESX)Orion Energy Systems Inc (NASDAQ:OESX) only has a market cap of $93 million. And while it had a pop in early 2017, it hasn't done much until recently.It's in the lighting business. Basically it designs, manufactures and installs commercial lighting systems and energy management solutions. That may not sound like a big business, but it depends on who your clients are.And recently it looks like OESX has landed a big client. Its stock is up 230% in the past 12 months and a whopping 477% YTD. And 100% in the past three months.It has landed a big fish to be sure. And if it's a big box retailer that's retrofitting its stores with energy-saving lighting, this is going to be a run that will last for a while.For now, however, few people are watching. Don't chase it, just buy in a little at a time. Sachem Capital Corp (SACH)Sachem Capital Corp (NYSE:SACH) is an interesting company. It's in the real estate investment trust (REIT) sector and is classified as a REIT. But it doesn't hold properties, its holds first mortgages on properties.It offers what's know in the business as "hard money loans", which are basically short-term (three years or less), secured non-banking loans for acquisition, renovation or development of properties in Connecticut, Massachusetts, New York and Rhode Island.It has about a $105 million market cap, and its performance has been solid. Year-to-date it's up 27%. And that should continue since both the REIT sector and the small cap sector are both doing well here. * 10 Small-Cap Stocks to Buy Before They Grow Up The real kicker is its 9.6% dividend. If you're looking for a long-term, small cap holding and a solid regional REIT play, look no further. New York Mortgage Trust (NYMT)New York Mortgage Trust (NASDAQ:NYMT) is another REIT, with all the benefits discussed earlier regarding being involved in two hot sectors at once.It also focuses on the mortgages and financial assets of a development or builder rather than the physical assets. With rates this low and likely headed lower, this is a very good time for a firm like NYMT since many developers will grab properties while rates are low and then can develop over time.In mid-July, the company offered an additional 20 million shares, which diluted current shareholders but has boosted its operating capital so it can make more deals while the market is hot.Its stock performance is about breakeven at this point, but it has a huge 13.1% dividend. Its $1.3 billion market cap also means it has aspirations to build a bigger company over time. Innovative Systems and Support (ISSC)Innovative Systems and Support Inc (NASDAQ:ISSC) has been building avionics and instrumentation for the airline industry since 1988. Its customers are a who's who of the major commercial airlines, logistics companies and governmental agencies.With a $94 million market cap, this is a niche player in the sector, but that simply means it's a reliable subcontractor to major contracts that are signed by various aviation companies. * 7 Strong Buy Stocks the Street Loves This has been a very good year for the company -- and its stock -- it's up 93% for the year and 150% YTD. With air travel expanding and online shopping continuing to grow, there's no doubt that airlines will be in need of the products ISSC delivers for many years to come. CorMedix (CRMD)CorMedix Inc (NASDAQ:CRMD) is a commercial-stage pharmaceutical company that focuses on its taurolidine technology to build a non-antibiotic, antimicrobial that can prevent bloodborne infections and inflammation in patients that are on IVs and catheters.It will be a contender with the long-time go-to, heparin.Earlier this month, the stock got a boost when the company announced that the Food and Drug Administration determined that it had passed its Phase III trial and doesn't need to expand its study further. That means CRMD is much closer to getting Neutrolin to market.It currently has a $219 million market cap and the stock has been doing well for a while. It's up 46% YTD and a whopping 214% in the past 12 months. CRMD has a good chance to be bought out or get a big licensing deal with a large pharmaceutical company. Adesto Technologies (IOTS)Adesto Technologies Corp (NASDAQ:IOTS) is a small chipmaker that specializes in non-volatile memory chips for the "Internet of Things" market.This is a massive long-term trend and as it expands, it's a great place for smaller chipmakers to grab a foothold. IOTS is a full stack IOT provider in the industrial, medical, consumer and communications sectors.The IOT semiconductor space is looking at a compounded annual growth rate (CAGR) of 25% until 2022 and CAGR of 35% for industrial IOT building blocks demand.It already works with the major players across its sectors and has a global presence. This means it will continue to grow with its partners. * 10 Companies I'd Love to See Go Public Right now, its market cap is a mere $247 million, but it's in a perfect position to grow alone or get acquired at a premium by a larger chip firm looking to gain market share in the sectors where IOTS thrives. Fluent (FLNT)Fluent Inc (NASDAQ:FLNT) is an online marketing platform for businesses and publishers.Remember, the old publishing model collapsed after the internet drove paper publishing into the ground. It also hit the direct mail business hard as well. Then, as everyone started filling your inbox with tons of junk mail, that became increasingly difficult as well.That left companies looking for ways to build their customer lists and create effective advertising that customers would see. And digital agencies like FLNT were born to market to and acquire customers.It has a $410 million market cap, so it has done well in the nine years since its founding and it continues to grow. Year-to-date it's up 54% and over the past 12 months it has returned 135%, yet still trades at a trailing P/E of 44.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy With Over 20% Upside From Current Levels * The 10 Best Stocks to Invest in for August * 6 Upcoming IPOs for August The post 7 A-Rated Stocks Under $10 appeared first on InvestorPlace.
BERKELEY HEIGHTS, N.J., July 17, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
Shares of the micro-cap biotech CorMedix Inc. (NYSE: CRMD ) were advancing Tuesday following the announcement of positive FDA feedback on the company's lead investigational drug. What Happened The FDA's ...
BERKELEY HEIGHTS, N.J., July 09, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
BERKELEY HEIGHTS, N.J., July 08, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it is set to join the US small-cap Russell 2000® Index, effective after the US market opens on July 1, according to a preliminary list of additions posted on June 21. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The Company will also be automatically added to the appropriate growth and value indexes. “We are very pleased with the upcoming addition to the Russell 2000 Index,” stated Khoso Baluch, CEO of CorMedix.
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that members of its board of directors and management team will ring the NYSE Closing Bell this afternoon in celebration of the successful results for the Company's lead product candidate Neutrolin® in the Phase 3 clinical study LOCK-IT-100. The Company began trading on the NYSE in March 2010.
BERKELEY HEIGHTS, N.J., May 16, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Berkeley Heights, New Jersey-based company said it had a loss of 22 cents per share. The pharmaceutical and medical device company posted revenue of $163,700 in the period. Its adjusted revenue was ...